著者
Shohei Yoshida Tomoaki Nakata Masanao Naya Mitsuru Momose Yasuyo Taniguchi Yoshimitsu Fukushima Masao Moroi Atsutaka Okizaki Akiyoshi Hashimoto Takatoyo Kiko Satoshi Hida Kazuya Takehana Kenichi Nakajima
出版者
The Japanese Circulation Society
雑誌
Circulation Reports (ISSN:24340790)
巻号頁・発行日
pp.CR-23-0031, (Released:2023-04-28)
参考文献数
25

Background: Definitions of cardiac sarcoidosis (CS) differ among guidelines. Any systemic histological finding of CS is essential for the diagnosis of CS in the 2014 Heart Rhythm Society statement, but not necessary in the Japanese Circulation Society 2016 guidelines. This study aimed to reveal the differences in outcomes by comparing 2 groups, namely CS patients with or without systemic histologically proven granuloma.Methods and Results: This study retrospectively included 231 consecutive patients with CS. CS with granulomas in ≥1 organs was diagnosed in 131 patients (Group G), whereas CS without any granulomas was diagnosed in the remaining 100 patients (Group NG). Left ventricular ejection fraction (LVEF) was significantly reduced in Group NG compared with Group G (44±13% vs. 50±16%, respectively; P=0.001). However, Kaplan-Meier curves showed that major adverse cardiovascular events (MACE)-free survival outcomes were comparable between the 2 groups (log-rank P=0.167). Univariable analyses showed that significant predictors of MACE were Groups G/NG, histological CS, LVEF, and high B-type natriuretic peptide (BNP) or N-terminal pro BNP concentrations, but none of these was significant in multivariable analyses.Conclusions: Overall risks of MACE were similar between the 2 groups despite different manifestations in cardiac dysfunction. The data not only validate the prognostic value of non-invasive diagnosis of CS, but also show the need for careful observation and therapeutic strategy in patients with CS without any granuloma.
著者
Osamu Manabe Masanao Naya Keiichiro Yoshinaga Noriko Oyama-Manabe Hiroshi Ohira Tadao Aikawa Nagara Tamaki
出版者
Japanese Society of Nuclear Cardiology
雑誌
Annals of Nuclear Cardiology (ISSN:21893926)
巻号頁・発行日
vol.3, no.1, pp.205-209, 2017 (Released:2017-10-31)
参考文献数
25
被引用文献数
1

Cardiac positron emission tomography (PET) has evolved over the several decades since its introduction. In current clinical practice and research, cardiac PET imaging is accepted as a valuable noninvasive modality for assessing various cardiac diseases such as coronary artery disease (CAD), cardiac tumors, and inflammatory diseases including cardiac sarcoidosis (CS). PET enables the imaging and evaluation of the cardiovascular system by myocardial perfusion with 82Rb, 13N-NH3 and 15O-H2O, and those of metabolism and inflammation using 18F-fluorodeoxyglucose (18F-FDG). PET has demonstrated superior diagnostic accuracy for the detection of CAD and also has well-established prognostic value. The combination of qualitative and absolute quantifications of myocardial blood flow enhances the diagnostic accuracy for multiple-vessel disease and provides incremental functional and prognostic information. In this review, we focus on the current and future roles of cardiac PET imaging, on the basis of our own experience.